CA3297005A1 - Conjugué anticorps-médicament et utilisation associée - Google Patents

Conjugué anticorps-médicament et utilisation associée

Info

Publication number
CA3297005A1
CA3297005A1 CA3297005A CA3297005A CA3297005A1 CA 3297005 A1 CA3297005 A1 CA 3297005A1 CA 3297005 A CA3297005 A CA 3297005A CA 3297005 A CA3297005 A CA 3297005A CA 3297005 A1 CA3297005 A1 CA 3297005A1
Authority
CA
Canada
Prior art keywords
antibody
drug conjugate
conjugate
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3297005A
Other languages
English (en)
Inventor
Xiao Gao
Fujun PAN
Xiwu HUI
Lu Zhao
Lixue FAN
Mo DAN
Yufen Wu
Xiongfei SUN
Mingxiao WANG
Bing Yao
Original Assignee
CSPC Megalith Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Megalith Biopharmaceutical Co Ltd filed Critical CSPC Megalith Biopharmaceutical Co Ltd
Publication of CA3297005A1 publication Critical patent/CA3297005A1/fr
Pending legal-status Critical Current

Links

CA3297005A 2023-06-29 2024-06-28 Conjugué anticorps-médicament et utilisation associée Pending CA3297005A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310780680.2 2023-06-29
CN202410125580.0 2024-01-30

Publications (1)

Publication Number Publication Date
CA3297005A1 true CA3297005A1 (fr) 2026-03-01

Family

ID=

Similar Documents

Publication Publication Date Title
CA3256212A1 (fr) Conjugués anticorps-médicament, procédés de préparation et utilisation associées
EP3797796A4 (fr) Conjugué anticorps-médicament et son utilisation
AU2021359562A9 (en) Antibody-drug conjugate and application thereof
EP4386006A4 (fr) Conjugué anticorps-médicament et son application
AU2022205057A9 (en) B7h4-targeted antibody-drug conjugates and methods of use thereof
EP4223785A4 (fr) Composition pharmaceutique comprenant un conjugué anticorps-médicament, et utilisation de la composition pharmaceutique
IL302122A (en) Antibody-drug conjugation and its application
CA3265517A1 (fr) Conjugués anticorps-médicament de facteur tissulaire et leurs utilisations
CA3297005A1 (fr) Conjugué anticorps-médicament et utilisation associée
HK40121438A (en) Antibody-drug conjugate and use thereof
HK40125899A (en) Anti-bdca2 antibody-drug conjugate and use thereof
CA3278529A1 (fr) Conjugué anticorps-médicament anti-bdca2 et son utilisation
HK40116350A (en) Antibody-drug conjugate and use thereof
CA3263031A1 (fr) Conjugué anticorps-médicament et son utilisation
HK40117339A (en) Anti-b7h3 antibody-drug conjugate and use thereof
HK40121726A (en) Antibody-drug conjugate and use thereof
CA3291392A1 (fr) Conjugué anticorps anti-pdl1-médicament et utilisation
HK40130441A (zh) 抗体-药物偶联物及其用途
HK40106517A (zh) 抗体药物偶联物及其应用
HK40117803A (en) B7h4 antibody-drug conjugate and use thereof
CA3249798A1 (fr) Conjugué anticorps-médicament anti-her3 et son utilisation
HK40111932A (en) Her3 antibody-drug conjugate and use thereof
HK40096914A (en) Antibody-drug conjugate and medical use thereof
HK40119417A (en) Gpc3 antibody-drug conjugate and use thereof
CA3280288A1 (fr) Conjugué anticorps-médicament et son utilisation